Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2017 - 2024)

Teva Pharmaceutical Industries has disclosed Asset Writedowns and Impairment across 8 years of filings, most recently posting $679.0 million for Q1 2024.

• Quarterly Asset Writedowns and Impairment rose 259.26% year-over-year to $679.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $1.6 billion (down 36.53% YoY) and the FY2023 annual result came in at $1.1 billion, down 55.95% from the prior year.
• Asset Writedowns and Impairment advanced to $679.0 million in Q1 2024, from $68.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $5.2 billion in Q3 2020 and troughed at $28.0 million in Q3 2022.
• A 5-year average of $666.8 million and a median of $227.0 million in 2021 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment soared 2433.66% — and 2021, when it slumped 99.1%.
• Tracing TEVA's Asset Writedowns and Impairment over 5 years: stood at $232.0 million in 2020, then dropped by 21.12% to $183.0 million in 2021, then jumped by 689.62% to $1.4 billion in 2022, then tumbled by 95.29% to $68.0 million in 2023, then surged by 898.53% to $679.0 million in 2024.
• Business Quant data shows TEVA's Asset Writedowns and Impairment at $679.0 million in Q1 2024, $68.0 million in Q4 2023, and $48.0 million in Q3 2023.